Linked Life Data

16080523

Source:http://linkedlifedata.com/resource/pubmed/id/16080523

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16080523rdf:typepubmed:Citationlld:pubmed
pubmed-article:16080523lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16080523lifeskim:mentionsumls-concept:C0021760lld:lifeskim
pubmed-article:16080523lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:16080523lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:16080523lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:16080523lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:16080523lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:16080523pubmed:issue4lld:pubmed
pubmed-article:16080523pubmed:dateCreated2005-8-5lld:pubmed
pubmed-article:16080523pubmed:abstractTextInterleukin (IL)-6 plays a central role as a differentiation and growth factor of tumor cells. IL-6 has been identified in a wide variety of malignancies, including head and neck squamous cell carcinomas (HNSCC). The aim of this study was to investigate the association between the serum levels of IL-6 in HNSCC patients and the biological characteristics of the tumor as well as the clinicopathological status of the patients. The circulating level of IL-6 in sera from patients with various HNSCC (n = 90) as well as from healthy normal controls (n = 39) was investigated. Serum IL-6 concentrations were determined as serum immunoreactivity using a quantitative sandwich enzyme immunoassay technique. For statistical analysis, the Kruskal-Wallis test was performed. The majority of the patients with HNSCC were found to have high serum IL-6 concentrations. The IL-6 levels in the sera of patients with cancer ranged from below the detection limit to 312.8 pg/ml (mean, 19.5 pg/ml). In contrast, the IL-6 serum levels in 39 healthy individuals ranged from below the detection limit to 52.2 pg/ml (mean, 6.0 pg/ml), with the concentration being significantly higher in HNSCC patients (p < 0.001). Furthermore, the correlation of the IL-6 serum concentration with tumor stage was significant (p = 0.04). Accordingly, there was a significant difference of IL-6 serum concentration of tumors with positive and negative lymph nodes (p = 0.045), with concentration being significantly higher in lymph node-positive tumors. Our data on elevated IL-6 serum levels in the majority of HNSCC cancer patients and its correlation with tumor stage and lymph node status suggest that serum IL-6 reflects the proliferative activity of the tumor in patients with head and neck cancer. IL-6 serum determinations might serve as a biological marker and help to identify advanced head and neck tumors.lld:pubmed
pubmed-article:16080523pubmed:languageenglld:pubmed
pubmed-article:16080523pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080523pubmed:citationSubsetIMlld:pubmed
pubmed-article:16080523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16080523pubmed:statusMEDLINElld:pubmed
pubmed-article:16080523pubmed:issn0250-7005lld:pubmed
pubmed-article:16080523pubmed:authorpubmed-author:HörmannKarlKlld:pubmed
pubmed-article:16080523pubmed:authorpubmed-author:RiedelFrankFlld:pubmed
pubmed-article:16080523pubmed:authorpubmed-author:HerzogDeniseDlld:pubmed
pubmed-article:16080523pubmed:authorpubmed-author:GötteKarlKlld:pubmed
pubmed-article:16080523pubmed:authorpubmed-author:NaimRaminRlld:pubmed
pubmed-article:16080523pubmed:authorpubmed-author:ZaissInkaIlld:pubmed
pubmed-article:16080523pubmed:issnTypePrintlld:pubmed
pubmed-article:16080523pubmed:volume25lld:pubmed
pubmed-article:16080523pubmed:ownerNLMlld:pubmed
pubmed-article:16080523pubmed:authorsCompleteYlld:pubmed
pubmed-article:16080523pubmed:pagination2761-5lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:meshHeadingpubmed-meshheading:16080523...lld:pubmed
pubmed-article:16080523pubmed:articleTitleSerum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.lld:pubmed
pubmed-article:16080523pubmed:affiliationDepartment of Otolaryngology, Head and Neck Surgery, University Hospital of Heidelberg at Mannheim, D-68135 Mannheim, Germany. frank.riedel@hno.ma.uni-heidelberg.delld:pubmed
pubmed-article:16080523pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16080523lld:pubmed